Novel multi‐peptide vaccination in Hla‐A2+ hormone sensitive patients with biochemical relapse of prostate cancer

A phase I/II trial was conducted to assess feasibility and tolerability of tumor associated antigen peptide vaccination in hormone sensitive prostate carcinoma (PC) patients with biochemical recurrence after primary surgical treatment.

[1]  H. Rammensee,et al.  Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA , 2005, European journal of immunology.

[2]  P. Schellhammer,et al.  Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[4]  J. Berzofsky,et al.  A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity , 2008, Cancer Immunology, Immunotherapy.

[5]  S. Akira,et al.  Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.

[6]  M. Resnick,et al.  Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era. , 2002, Urology.

[7]  H. Ragde,et al.  Presentation of prostate tumor antigens by dendritic cells stimulates T‐cell proliferation and cytotoxicity , 1996, The Prostate.

[8]  J. Sosman,et al.  Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer , 2002, Cancer Immunology, Immunotherapy.

[9]  A. Marrari,et al.  Vaccination therapy in prostate cancer , 2007, Cancer Immunology, Immunotherapy.

[10]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[11]  K. Jooss,et al.  Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy , 2006, Clinical Cancer Research.

[12]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[13]  P. Sprenkle,et al.  Pathologic effects of testosterone deprivation , 2007, Current opinion in urology.

[14]  M. Bednarek,et al.  The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. , 1991, Journal of immunology.

[15]  A. Tolcher,et al.  Management of high risk metastatic prostate cancer: the case for novel therapies. , 2006, The Journal of urology.

[16]  A. Banham,et al.  CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients1 , 2006, The Journal of Immunology.

[17]  H. Rammensee,et al.  Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. , 2000, Cancer research.

[18]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  H. Grey,et al.  Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  K. Meyer zum Büschenfelde,et al.  Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells , 1994, Cancer Immunology, Immunotherapy.

[21]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[22]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[23]  L. Liau,et al.  The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity1 , 2006, The Journal of Immunology.

[24]  H. Rammensee,et al.  Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA , 2006, European journal of immunology.

[25]  E. Rieber,et al.  Vaccination of hormone‐refractory prostate cancer patients with peptide cocktail‐loaded dendritic cells: Results of a phase I clinical trial , 2006, The Prostate.

[26]  G. Gaudernack,et al.  Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells , 2006, Cancer Immunology, Immunotherapy.

[27]  C. Higano,et al.  Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer , 2008, Cancer.

[28]  W. Cavanagh,et al.  Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. , 2004, The Journal of urology.

[29]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[30]  L. Kanz,et al.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000 .

[31]  S. Stevanović.  Identification of tumour-associated t-cell epitopes for vaccine development , 2002, Nature Reviews Cancer.

[32]  Michael W Kattan,et al.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.

[33]  J. Schlom,et al.  In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. , 1997, Journal of the National Cancer Institute.

[34]  J. Earle,et al.  Failure after primary radiation or surgery for prostate cancer: differences in response to androgen ablation. , 2004, The Journal of urology.

[35]  H. Ragde,et al.  Report of immune monitoring of prostate cancer patients undergoing T‐cell therapy using dendritic cells pulsed with HLA‐A2‐specific peptides from prostate‐specific membrane antigen (PSMA) , 1998, The Prostate.

[36]  F. Marshall,et al.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. , 1999, Cancer research.

[37]  E. Venkatraman,et al.  Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.